Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-22 of 22 for your search:
Cancer Type/Condition:
Soft tissue sarcoma, child
Stage/Subtype:
metastatic childhood soft tissue sarcoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Study of Risk-Based Therapy Comprising Observation Only, Adjuvant Radiotherapy, or Adjuvant Chemoradiotherapy or Neoadjuvant Chemoradiotherapy, Surgery, and Adjuvant Chemotherapy With or Without Radiotherapy in Young Patients With Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 30 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ARST0332
, ARST0332, NCT00346164
2.
Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
13 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-302
, NCT00538239
3.
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
BMT 0499 Solid
, NCT00179816
4.
Phase I/II Study of Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 and Doxorubicin Hydrochloride in Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-16227A
, 16227A, 8131, NCT00720174
5.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
6.
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
10 and over
Sponsor:
Other
Protocol IDs:
INST 0909
, 3066K1, 3066K1-1208, 20091334, NCT00996346
7.
Phase II Pilot Study of Induction Chemotherapy Followed By Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
4 to 35
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0259
, NCT00047372
8.
Phase II Pilot Study of Irinotecan and Carboplatin as Upfront Window Therapy in Patients With Newly Diagnosed Intermediate- or High-Risk Rhabdomyosarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
30 and under at diagnosis
Sponsor:
NCI
Protocol IDs:
MSKCC-03099
, NCT00077285
9.
Phase II Study of Chemotherapy Comprising Doxorubicin Hydrochloride and Ifosfamide Followed By Etoposide and Ifosfamide in Patients With Sporadic or Neurofibromatosis Type 1-Associated High-Grade Stage III or IV Malignant Peripheral Nerve Sheath Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
SARC-006
, 006, NCI-06-C-0043, NCI-P6452, NCT00304083, UMN-2007CG077
10.
Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
11.
Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
CINJ-3330
, NCT00161187
12.
Trial of Dasatinib in Advanced Sarcomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 13
Sponsor:
Other
Protocol IDs:
SARC009
, NCT00464620
13.
Phase 2 Study in Patients With MiT Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
13 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-204
, NCT00557609
14.
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
NCI, Other
Protocol IDs:
05-326
, NCT00592293
15.
A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP13-0707
, EudraCT Number: 2007-006719-21, NCT00668148
16.
Phase I Study of Intrathecal Iodine I 131 Monoclonal Antibody 8H9 in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
MSKCC-03133
, NCT00089245
17.
Phase I Study of Lexatumumab With or Without Recombinant Interferon Gamma in Pediatric Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 30
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0040
, NCI-P6981, NCT00428272
18.
Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
19.
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0007
, 08-C-0007, NCI-P6068, 7458, NCT00556881
20.
Phase I Study of Total Marrow Irradiation With Helical Tomotherapy Image-Guided Intensity-Modulated Radiotherapy Followed by Alkylator-Intense Conditioning Comprising Busulfan, Melphalan, and Thiotepa and Autologous CD34+ Hematopoietic Progenitor Cell Transplantation in Patients With High-Risk or Relapsed Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS023
, UMN-2005LS023, UMN-MT2004-30, NCT00623077
21.
Phase I Study of Pazopanib Hydrochloride in Pediatric Patients With Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ADVL0815
, ADVL0815, NCT00929903
22.
Pilot Study of Cyclophosphamide and Cryoablation in Patients With Advanced or Metastatic Epithelial Solid Cancer
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
JHOC-J0685
, NA_00003073, J0685, NCT00499733
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
